Genus plc (LON:GNS)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX 2,338.00
-72.00 (-2.99%)
Nov 10, 2026, 4:35 PM GMT
Genus Market Cap
Genus has a market cap or net worth of 1.5 billion as of November 10, 2026. It is the 6,529th most valuable company in the world and the 168th biggest in the United Kingdom. Its market cap has decreased by 4.94% in one year.
Market Cap
1.50B
Enterprise Value
1.57B
Revenue
658.10M
Global Rank
Country Rank
#168 United Kingdom
PE Ratio
5.50
ChartMarket Cap Chart
Since January 30, 1998, Genus's market cap has increased from 31.03M to 1.50B, an increase of 4,747.74%. That is a compound annual growth rate of 14.43%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 10, 2026 | 1.50B | -13.37% |
| Dec 31, 2025 | 1.74B | 70.54% |
| Dec 31, 2024 | 1.02B | -28.43% |
| Dec 29, 2023 | 1.42B | -27.10% |
| Dec 30, 2022 | 1.95B | -39.35% |
| Dec 31, 2021 | 3.22B | 18.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Oxford Nanopore Technologies | 1.97B |
| Oxford Biomedica | 666.81M |
| PureTech Health | 300.10M |
| Avacta Group | 262.86M |
| Bioventix | 100.58M |
| Scancell Holdings | 96.98M |
| 4basebio | 81.58M |
| Faron Pharmaceuticals Oy | 64.03M |